Episode description
Episode description
More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I. DAPA MI
Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate'
https://www.medscape.com/s/viewarticle/998378
- NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
II. Blood Transfusion Strategy Post MI
In MI With Anemia, Results May Favor Liberal Transfusion: MINT
https://www.medscape.com/viewarticle/998376
- MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983
- REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201
- PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
III. FACTOR XI
Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA
https://www.medscape.com/viewarticle/998418
Asundexian Phase 3 AF Study Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/998665
- Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872
IV. Renal Denervation
FDA Panel Split on Efficacy of Spyral Renal Denervation
https://www.medscape.com/viewarticle/995800
FDA OKs Symplicity Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998664
- SPYRAL HTN OFF MED -- https://doi.org/10.1016/S0140-6736(20)30554-7
- SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6
- SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net